Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.330
-0.080 (-2.35%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Pyxis Oncology Employees
Pyxis Oncology had 56 employees as of December 31, 2025. The number of employees increased by 12 or 27.27% compared to the previous year.
Employees
56
Change (1Y)
12
Growth (1Y)
27.27%
Revenue / Employee
$197,107
Profits / Employee
-$1,584,411
Market Cap
277.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 56 | 12 | 27.27% |
| Dec 31, 2024 | 44 | -6 | -12.00% |
| Sep 30, 2024 | 54 | -13 | -19.40% |
| Jun 30, 2024 | 55 | -17 | -23.61% |
| Mar 31, 2024 | 51 | -22 | -30.14% |
| Dec 31, 2023 | 50 | -25 | -33.33% |
| Sep 30, 2023 | 67 | -6 | -8.22% |
| Jun 30, 2023 | 72 | 5 | 7.46% |
| Mar 31, 2023 | 73 | 9 | 14.06% |
| Dec 31, 2022 | 75 | 19 | 33.93% |
| Sep 30, 2022 | 73 | 28 | 62.22% |
| Jun 30, 2022 | 67 | 29 | 76.32% |
| Mar 31, 2022 | 64 | 26 | 68.42% |
| Dec 31, 2021 | 56 | - | - |
| Sep 30, 2021 | 45 | - | - |
| Jun 30, 2021 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 161 |
| Upstream Bio | 75 |
| Sionna Therapeutics | 59 |
| Immuneering | 57 |
| Camp4 Therapeutics | 48 |
| Vicore Pharma Holding AB | 46 |
| Cue Biopharma | 29 |
| Palisade Bio | 14 |
PYXS News
- 9 days ago - Pyxis Oncology price target raised to $8 from $7 at H.C. Wainwright - TheFly
- 10 days ago - Pyxis Oncology price target raised to $19 from $12 at Wells Fargo - TheFly
- 10 days ago - Pyxis Oncology announces updated results from micvotabart pelidotin study - TheFly
- 10 days ago - Pyxis Oncology Transcript: Study update - Transcripts
- 10 days ago - Pyxis Oncology Press release: Study update - Filings
- 10 days ago - Pyxis Oncology Slides: Study update - Filings
- 10 days ago - Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - GlobeNewsWire
- 11 days ago - Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - GlobeNewsWire